normal tissues. Increased expression of 3 L1 retrotransposons (L1-FGGY, L1-ATP8P1 and L1-SVEP1) was significantly associated with poor clinical outcome, large tumor size, central location or smoking history. Among these three, the L1-FGGY occurred frequently in LUSC tumors (38%, 19 out of 50 LUSC cases) and it promoted cell proliferation and invasion, inhibited cell apoptosis, as well as facilitated tumorigenesis in vitro and vivo. Increased L1-FGGY expression in tumors was coupled with decreased expression of FGGY gene, implicating the L1 insertion into FGGY disrupted the expression and function of the tumor-suppressor gene. Lastly, we observed that the reverse transcription inhibitors, nevirapine (NVR) and efavirenz (EFV) dramatically suppressed L1-FGGY expression and elevated FGGY expression, therefore inhibited the proliferation and invasion of L1-FGGY positive LUSC cells both in vitro and vivo. Conclusion: In conclusion, L1-FGGY retrotransposition was a frequent genomic event in LUSC that promoted the development and progression of LUSC and could be a novel prognosis marker and potential therapeutic target for LUSC. Background: Docetaxel plus ramucirumab (DTX+RAM) prolongs survival in patients with non-small cell lung cancer (NSCLC) with disease progression after platinum-based therapy. We assessed the efficacy and safety, especially the incidence of febrile neutropenia (FN), in patients who received DTX+RAM. Method: Consecutive patients who received DTX+RAM between August 2016 and May 2018 were reviewed retrospectively. Results: A total 68 patients received DTX+RAM. The patients' characteristics were as follows: male/female, 42/26 patients; median age (range), 64 (40-74) years; PS 0/1/2, 18/43/7 patients; and Ad/Sq, 58/10 patients. The median number of DTX+RAM treatment cycles was 4 (range, 1-15). Primary prophylactic pegylated (PEG)-granulocyte-colony stimulating factor (G-CSF) was performed in 29 (57%) patients. Secondary prophylactic PEG-G-CSF was performed in 6 (9%) patients. Therapeutic use of PEG-G-CSF was performed in 7 (10%) patients. The response rate and disease control rate were 30.9% (95% confidence interval [CI], 20.1-41.7) and 61.8% (95% CI, 50.4-73.0), respectively. The median progression-free survival period was 5.1 (95% CI, 2.8-6.8) months. The median overall survival period was 16.4 (95% CI, 10.3-not reached) months. Eighteen (26%) patients had grade 3/4 neutropenia. FN did not occur in any of the patients who had received primary prophylactic PEG-G-CSF, whereas FN was observed in 21% of the patients in whom primary prophylactic PEG-G-CSF was not performed. Background: Rearrangement of RET is identified as an oncogenic alteration in lung cancer. However, studies about characteristics of RET rearrangement in lung cancers are still limited, and several reports were conflicting. Our aim was to demonstrate the clinical and molecular features of RET rearrangement in Chinese lung cancers. Method: We reviewed genomic profiling data of biopsies (including either tissue or plasma) from 6125 lung cancer patients sequenced in a CLIA-certified laboratory from 2015 to 2017. Patient characteristics, including age, gender and histology classification were collected. Results: A total of 106 RET rearrangements in 84 patients (1.37%, 84/6125) were identified. RET rearrangement had a tendency to occur in female, adenocarcinoma, with a median age of 58 years. KIF5B-RET fusion was the most frequently occurred subtypes, identified in 53.8% (57/106) RET rearrangements and 67.9% (57/84) of patients, followed by CCDC6-RET and NCOA4-RET. Besides, several rare and novel RET fusion partners were identified, to the best of our knowledge, including TSSK4, SORBS1, SIRT1, PTPRK, ADD3-AS1, PRKG1, IL2RA, CCNYL2, CCDC186 and ANKS1B. We further investigated the concurrent and exclusive genomic alterations in RET-rearranged patients. TP53 was the most commonly seen concurrent mutation, occurring in 42.5% (20/47) of patients, which was followed by EGFR (14.9%, 7/47). KIF5B-RET subtype was fully mutual exclusive with EGFR mutation, suggesting that KIF5B-RET was a strong oncogenic driver mutation. RET fusion partners of the 7 patients harboring concurrent EGFR and RET rearrangement were all non-KIF5B. In addition, we observed that allelic fraction of first-generation EGFR-TKI sensitizing mutation was higher than non-KIF5B-RET in each individual patient, indicating that non-KIF5B-RET fusion might function as a potential acquired resistance mechanism to EGFR tyrosine kinase inhibitors. Clinical outcomes of cabozantinib, a RET kinase inhibitor, were available in six patients with RET-rearrangement, and the median treatment period of cabozantinib for these patients was 5 months. A stage IV adenocarcinoma patient developed resistance to osimertinib and followed NGS revealed that he harbored concurrent CCNYL2-RET fusion and EGFR mutation. After the combinatorial treatment of osimertinib and cabozantinib, he achieved stable disease (SD) with a PFS of 5 months before disease progression. Conclusion: Lung cancer patients with RET-rearrangement displayed identifiable clinical characteristics and heterogeneous molecular distribution. The investigation of clinical and molecular pattern of RET-rearrangements might be helpful to provide basic knowledge for personalized diagnosis and clinical considerations. Further investigations are needed in the fields of potential sensitivities among different fusion variants and resistance mechanism to RET inhibition.
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